HIV Medicine

Article	Citations
Coronavirus disease 2019 (COVID‐19) outcomes in HIV/AIDS patients: a systematic review	131
Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV	119
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0	109
Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany	59
Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021	56
Impact of coronavirus disease (COVID‐19) on HIV testing and care provision across four continents	49
Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy	48
Prognosis of coronavirus disease 2019 (COVID‐19) in patients with HIV infection in New York City	37
Clinical epidemiology and outcome of HIV‐associated talaromycosis in Guangdong, China, during 2011–2017	33
The burden of non‐communicable diseases and mortality in people living with HIV (PLHIV) in the pre‐, early‐ and late‐HAART era	30
Managing HIV‐associated inflammation and ageing in the era of modern ART	28
Chems4EU: chemsex use and its impacts across four European countries in HIV‐positive men who have sex with men attending HIV services	26
Public understanding and awareness of and response to monkeypox virus outbreak: A cross‐sectional survey of the most affected communities in the United Kingdom during the 2022 public health emergency	25
Qualitative assessment of anti‐SARS‐CoV‐2 spike protein immunogenicity (QUASI) after COVID‐19 vaccination in older people living with HIV	24
Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world evidence	22
Efficacy and durability of two‐ vs. three‐drug integrase inhibitor‐based regimens in virologically suppressed HIV‐infected patients: Data from real‐life ODOACRE cohort	20
COVID‐19 in hospitalized HIV‐positive and HIV‐negative patients: A matched study	20
Late diagnosis of HIV: An updated consensus definition	19
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium	18
Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor‐ to dolutegravir‐based antiretroviral therapy: A prospective cohort study in Lesotho (DO‐REAL study)	17
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019	16
Utility of CD4 count measurement in the era of universal antiretroviral therapy: an analysis of routine laboratory data in Botswana	16
Interrogating the impact of combination antiretroviral therapies on HIV‐associated neurocognitive disorders	16
What do the changing patterns of comorbidity burden in people living with HIV mean for long‐term management? Perspectives from European HIV cohorts	16
Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG	15

Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023	15
A review of reported cases of HIV pre‐exposure prophylaxis failure with resultant breakthrough HIV infections	15
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials	14
Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV‐1‐infected patients: a real‐world study in Japan	14
Prevalence of mental health conditions among people living with HIV during the COVID‐19 pandemic: A rapid systematic review and meta‐analysis	14
Clinical outcomes after first‐line HIV treatment failure in South Africa: the next cascade of care	14
Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy	14
Comorbidities in women living with HIV: A systematic review	13
BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022	13
Clinical outcomes of patients with and without HIV hospitalized with COVID‐19 in England during the early stages of the pandemic: a matched retrospective multi‐centre analysis (RECEDE‐C19 study)	13
UK guideline for the use of HIV post‐exposure prophylaxis 2021	12
A qualitative study of the impact of coronavirus disease (COVID‐19) on psychological and financial wellbeing and engagement in care among men who have sex with men living with HIV in Thailand	12
Acquired immune deficiency syndrome (AIDS) and late presentation in Poland – data from Test and Keep in Care (TAK) Polska project	12
Low awareness of and willingness to use PrEP in the Chinese YMSM: An alert in YMSM HIV prevention	12
Prevalence and incidence of pre‐diabetes and diabetes mellitus among people living with HIV in Ghana: Evidence from the EVERLAST Study	12
Diagnostic value of serological biomarkers for detection of non‐alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV	12
Gender difference in all‐cause mortality of people living with HIV in Iran: findings from a 20‐year cohort study	11
Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir‐ than with efavirenz‐based antiretroviral therapy	11
Evaluation of an inner city HIV pre‐exposure prophylaxis service tailored to the needs of people who inject drugs	11
Caspofungin combined with TMP/SMZ as a first‐line therapy for moderate‐to‐severe PCP in patients with human immunodeficiency virus infection	11
Incidence of recently acquired hepatitis C virus infection among HIV‐infected patients in southern Spain	11
Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV	11
The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV‐infected patients on suppressive antiretroviral therapy	11
Polypharmacy and potential drug–drug interactions for people with HIV in the UK from the Climate‐HIV database	11
Transmitted HIV‐1 drug resistance in a large international cohort using next‐generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study	11
Dyslipidaemia after switch to tenofovir alafenamide (TAF)‐based cART regimens in a cohort of HIV‐positive patients: what clinical relevance?	11
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age	11
Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade	11
COVID‐19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID‐19 pandemic in England	11
Estimated glomerular filtration rate slopes on tenofovir alafenamide	11
Characteristics and viral suppression among people living with HIV from the National Free Antiretroviral Therapy Programme, 2019	10
Mortality and AIDS‐defining events among young people following transition from paediatric to adult HIV care in the UK	10
Prevalence of obesity and disturbances in glucose homeostasis in HIV‐infected subjects and general population – missed diagnoses of diabetes?	10
Trends of age‐related non‐communicable diseases in people living with HIV and comparison with uninfected controls: A nationwide population‐based study in South Korea	10
Virological failure and HIV drug resistance among adults living with HIV on second‐line antiretroviral therapy in the Asia‐Pacific	10
Alarming rates of virological failure and HIV‐1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY‐study in Cameroon	10
HIV DNA reservoir and elevated PD‐1 expression of CD4 T‐cell subsets particularly persist in the terminal ileum of HIV‐positive patients despite cART	10
Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors	10
British HIV Association/British Association for Sexual Health and HIV/British Infection Association adult HIV testing guidelines 2020	10
Re‐assessing the late HIV diagnosis surveillance definition in the era of increased and frequent testing	9
Time trends in cancer incidence in Australian people living with HIV between 1982 and 2012	9
Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors	9
Increased targeted HIV testing and reduced undiagnosed HIV infections among gay and bisexual men	9
Long‐acting injectable cabotegravir forPrEP: A game‐changer inHIVprevention?	9
Plasmablastic lymphoma in Johannesburg, South Africa, in the era of widescale antiretroviral therapy use	9
Comorbidities and co‐medications among 28 089 people living with HIV: A nationwide cohort study from 2009 to 2019 in Japan	9
Outcomes of persistent low‐level viremia among HIV patients on antiretroviral therapy: A prospective cohort study	8
The success of HIV combination prevention: The Dean Street model	8
Where are we with pre‐exposure prophylaxis use in Central and Eastern Europe? Data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group	8
Long‐term success for people living with HIV: A framework to guide practice	8

Increasing HIV early diagnosis by implementing an automated screening strategy in emergency departments	8
Participation, retention and uptake in a multicentre pre‐exposure prophylaxis cohort using online, smartphone‐compatible data collection	8
Potentially inappropriate medications in older adults living with HIV	8
Barriers and facilitators to HIV Pre‐Exposure Prophylaxis (PrEP) in Specialist Sexual Health Services in the United Kingdom: A systematic review using the PrEP Care Co	8
FRAX assessment in people ageing with HIV	8
The association between use of chemsex drugs and HIV clinic attendance among gay and bisexual men living with HIV in London	8
National strategies for vaccination against COVID‐19 in people living with HIV in Central and Eastern European region	7
Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort	7
Impact of COVID‐19 on HIV late diagnosis in a specialized German centre	7
Post‐exposure prophylaxis in the era of pre‐exposure prophylaxis	7
Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial	7
Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort	7
Improving healthcare for patients with HIV, tuberculosis and hepatitis C in eastern Europe: a review of current challenges and important next steps	7
Pre‐treatment and acquired antiretroviral drug resistance among people living with HIV in Tianjin, China	7
Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score	7
Longitudinal analysis of new‐onset non‐AIDS‐defining diseases among people living with HIV: A real‐world observational study	7
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real‐world setting in Belgium	7
Sexual risk and HIV testing disconnect in men who have sex with men (MSM) recruited to an online HIV self‐testing trial	7
Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance	7
Factors partitioning physical frailty in people aging with HIV: A classification and regression tree approach	7
People with HIV have a higher risk of COVID‐19 diagnosis but similar outcomes to the general population	7
Cognitive ageing is premature among a community sample of optimally treated people living with HIV	7
Same‐day antiretroviral therapy initiation for people living with HIV who have tuberculosis symptoms: a systematic review	7
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment	7
The impact of COVID‐19‐related restrictions in 2020 on sexual healthcare use, pre‐exposure prophylaxis use, and sexually transmitted infection incidence among men who have sex with men in A	7
Respiratory symptoms and chronic bronchitis in people with and without HIV infection	7
Relationship of polypharmacy to HIV RNA suppression in people aged ≥ 50 years living with HIV	6
Pneumocystis jirovecii pneumonia PCR test on upper respiratory tract swab	6
Objective and subjective rapid frailty screening tools in people with HIV	6
High residual inflammation despite HIV viral suppression: Lessons learned from real‐time adherence monitoring among people with HIV in Africa	6
Estimation of the determinants for HIV late presentation using the traditional definition and molecular clock‐inferred dates: Evidence that older age, heterosexual risk group and more recen	6
Virological response and resistance profile in highly treatment‐experienced HIV‐1‐infected patients switching to dolutegravir plus boosted darunavir in clinical practice	6
HIV‐associated neurocognitive impairment in stable people living with HIV on ART in rural Tanzania	6
Effectiveness of integrase strand transfer inhibitors in HIV‐infected treatment‐experienced individuals across Europe	6
The role of CD8 T cells in controlling HIV beyond the antigen‐specific face	6
Immune restoration affects 10‐year survival in people living with HIV/AIDS	6
Adverse perinatal outcomes associated with timing of initiation of antiretroviral therapy: Systematic review and meta‐analysis	6
Trends in antiretroviral use in pregnancy in the UK and Ireland, 2008–2018	6
Chemsex and antiretroviral prescribing in an HIV cohort in Brighton, UK	6
Immune response to mRNA‐based COVID‐19 booster vaccination in people living with HIV	6
Facilitators and barriers of women's participation in HIV clinical research in Switzerland: A qualitative study	6
Effects of antiretroviral therapy on proprotein convertase subtilisin/kexin 9: focus on lipids, inflammation and immunovirological parameters	6
Three‐year efficacy of switching to dolutegravir plus lamivudine: A real‐world study	6
Pretreatment drug resistance in people living with HIV: A large retrospective cohort study in Chongqing, China	6
Endothelial activation is associated with intestinal epithelial injury, systemic inflammation and treatment regimen in children living with vertically acquired HIV‐1 infection	6
Incidence rate, predictors and outcomes of interruption of HIV care: nationwide results from the Belgian HIV cohort	6
Late diagnosis of HIV in 2022: Why so little change?	6
Bioactive phytocompound mulberroside C and endophytes of Morus alba as potential inhibitors of HIV‐1 replication: a mechanistic evaluation	6
HIV/AIDS post‐exposure prophylaxis knowledge and uptake among health professionals in Africa: Systematic review and meta‐analysis	6
Effect of an opt‐out point‐of‐care HIV‐1 nucleic acid testing intervention to detect acute and prevalent HIV infection in symptomatic adult outpatients and reduce HIV transmission in Kenya: a randomiz	6
COVID‐19 research: an opinion piece	6
“Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV”	5
Predictors of in‐hospital mortality among HIV‐positive patients presenting with an acute illness to the emergency department	5
Frailty and frailty screening: A qualitative study to elicit perspectives of people living with HIV and their healthcare professionals	5
Failure to eradicate Helicobacter pylori infection is more frequent among HIV‐positive patients	5
Modelling the impact of an HIV testing intervention on HIV transmission among men who have sex with men in China	5
Abstracts	5
Prevalence of HIV‐associated neurocognitive disorder (HAND) in Turkey and assessment of Addenbrooke’s Cognitive Examination Revised (ACE‐R) test as a screening tool	5
Integrase strand transfer inhibitor treatment does not increase the incidence of immune reconstitution inflammatory syndrome in HIV‐infected Koreans	5
Why we need to re‐define long‐term success for people living with HIV	5
Epidemiology of HIV infection and associated behaviours among people who inject drugs in England, Wales, and Northern Ireland: Nearly 40 years on	5
British HIV Association guidelines for the management of HIV‐2 2021	5
Mortality under early access to antiretroviral therapy vs. Eswatini’s national standard of care: the MaxART clustered randomized stepped‐wedge trial	5
Association of low‐level viremia with mortality among people living with HIV on antiretroviral therapy in Dehong, Southwest China: A retrospective cohort study	5
Transitioning from HIV post‐exposure prophylaxis to pre‐exposure prophylaxis in men who have sex with men	5
Factors associated with human immunodeficiency virus‐1 low‐level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China	5
Healthcare delivery for HIV‐positive people with tuberculosis in Europe	5
In utero and peripartum antiretroviral exposure as predictor of cognition in 6‐ to 10‐year‐old HIV‐exposed Ugandan children – a prospective cohort study	5
Epidemiology, comorbidities at diagnosis and outcomes associated with HIV late diagnosis from 2010 to 2019 in a Belgian reference centre: A retrospective study	5
Cardiac chamber volumes and left ventricular mass in people living with HIV and matched uninfected controls	5
Prediction of future cardiovascular events by Framingham, SCORE and asCVD risk scores is less accurate in HIV‐positive individuals from the HIV‐HEART Study compared with the general population	5
A matched cohort study investigating premature, accentuated, and accelerated aging in people living with HIV	5
Menopausal status, age and management among women living with HIV in the UK	5
Immune response to ART initiation in advanced HIV infection	5
The data‐collection on adverse effects of anti‐HIV drugs (D:A:D) model for predicting cardiovascular events: External validation in a diverse cohort of people living with HIV	5
The impact of COVID‐19 on HIV testing in the UK’s first Fast‐Track HIV city	5
Same‐dayand rapid initiation of antiretroviral therapy in people living withHIVin Asia. How far have we come?	5
Association of body mass index with immune recovery, virological failure and cardiovascular disease risk among people living with HIV	5
Blood‐borne virus testing in emergency departments – a systematic review of seroprevalence, feasibility, acceptability and linkage to care	5
Use of antiretroviral therapy in pregnancy and association with birth outcome among women living with HIV in Denmark: A nationwide, population‐based cohort study	5

What problems associated with ageing are seen in a specialist service for older people living with HIV?	5
Immune reconstitution inflammatory syndrome‐associated Graves disease in HIV‐infected patients: clinical characteristics and response to radioactive iodine therapy	5
Obesity in women living with HIV aged 45–60 in England: An analysis of the PRIME study	5
Is contact between men who have sex with men and non‐governmental organizations providing harm reduction associated with improved HIV outcomes?	5
Ageing with HIV in the United States: Changing trends in inpatient hospital stays and comorbidities, 2003–2015	5
Weight changes, metabolic syndrome and all‐cause mortality among Asian adults living with HIV	5
Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS)	5
Delayed HIV diagnosis during the COVID‐19 pandemic in Poland: A call for targeted HIV testing for those under suspicion of SARS‐CoV‐2	5
HIV prevalence and HIV clinical outcomes of transgender and gender‐diverse people in England	4
Economic impact on direct healthcare costs of missing opportunities for diagnosing HIV within healthcare settings	4
Lipopolysaccharide induces platelet activation in HIV patients: the role of different viral load patterns	4
Multidisciplinary collaborative integrated management of increasingly prominent HIV complications in the post‐cART era	4
Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance	4
Integration of HIV services with primary care in Yangon, Myanmar: a retrospective cohort analysis	4
Low frequency of cytomegalovirus (CMV) disease despite high prevalence of CMV viraemia in patients with advanced HIV infection: a clinical and immunological 48‐week follow‐up study	4
Prescribing patterns of antiretroviral treatments during pregnancy for women living with HIV in Canada 2004–2020: A surveillance study	4
Estimating the risk of mortality attributable to recent late HIV diagnosis following admission to the intensive care unit: A single‐centre observational cohort study	4
British HIV Association guidelines on the management of opportunistic infection in people living with HIV: the clinical management of gastrointestinal opportunistic infections 2020	4
The benefits of tenofovir discontinuation with or without bisphosphonate therapy in osteoporotic people living with HIV	4
Follicle‐stimulating hormone in postmenopausal women living with HIV: a prevalence study	4
Advanced HIV disease: A review of diagnostic and prophylactic strategies	4
Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: cross‐sectional and longitudinal analyses	4
HCV reinfection after HCV therapy among HIV/HCV‐coinfected individuals in Europe	4
Body mass index and noninfectious comorbidity in HIV‐positive patients commencing antiretroviral therapy in Zimbabwe	4
Short‐ and medium‐term prognosis of HIV‐infected patients receiving intensive care: a Brazilian multicentre prospective cohort study	4
Excess liver‐related mortality among people with AIDS compared to the general population: an Italian nationwide cohort study using multiple causes of death	4
Potential drug–drug interactions between antiretroviral drugs and comedications, including dietary supplements, among people living with HIV: A clinical survey	4
Anticholinergic medications associated with falls and frailty in people with HIV	4
The recent natural history of human papillomavirus cervical infection in women living with HIV: A scoping review of meta‐analyses and systematic reviews and the construction of a hypothetic	4
Language matters: The importance of person‐first language and an introduction to the People First Charter	4
A retrospective cohort study of early mortality among patients with HIV/TB co‐infection in Shanghai municipality	4
Associations of marijuana with markers of chronic lung disease in people living with HIV	4
Predictors of low‐level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort	4
Baseline characteristics of a prospective cohort study of aging and cardiovascular diseases among people living with HIV	4
Who’s slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first‐line HIV treatment in Uganda and South Africa	4
Late diagnosis of HIV infection in Warsaw: Estimating the scale of the problem and demographic trends	4
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium	4